skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Optimal management of familial hypercholesterolemia: treatment and management strategies

Review

(2221) Views  (916) Full article downloads

Authors: Mohammad Hassan Nemati, Behrooz Astaneh

Published Date December 2010 Volume 2010:6 Pages 1079 - 1088
DOI: http://dx.doi.org/10.2147/VHRM.S8283

Mohammad Hassan Nemati1, Behrooz Astaneh2
1Cardiac Surgery Department, Faghihi Hospital, 2 Vice Chancellor for Research Department, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract: Familial hypercholesterolemia is an autosomally dominant disorder caused by various mutations in low-density lipoprotein receptor genes. This will lead to elevated levels of total and low-density lipoprotein cholesterol, which may in turn lead to premature coronary atherosclerosis and cardiac-related death. The symptoms are more severe in the homozygous type of the disease. Different options for the treatment of affected patients are now available. Diet therapy, pharmacologic therapy, lipid apheresis, and liver transplantation are among the various treatments. We clinically review the treatment and management strategies for the disease in order to shed light on the optimal management of familial hypercholesterolemia.

Keywords: familial hypercholesterolemia, homozygote, heterozygote, Iran






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Impact of a diabetic foot care education program on lower limb amputation rate
Low high-density lipoprotein cholesterol: current status and future strategies for management
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Insulin therapy in critically ill patients
Inhaled treprostinil and pulmonary arterial hypertension
Lower extremity arterial injuries over a six-year period: outcomes, risk factors, and management
Stent-grafts in the management of life-threatening hemorrhage following inadvertent femoral catheterization in high-risk patients: report of two cases and review of the literature
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University